Comparison of 26-week efficacy and tolerability of telmisartan and atenolol, in combination with hydrochlorothiazide as required, in the treatment of mild to moderate hypertension: A randomized, multicenter study

Clinical Therapeutics

Volumn 23, Issue 1, 2001, Pages 108-123

  Freytag, Frank ^a   Schelling, Adre ^b   Meinicke, Thomas ^c   Deichsel, Guntram ^c  

^a Kreiskrankenhaus Gunzenhausen   (Germany)

^b SINT FRANCISCUS GASTHUIS   (Netherlands)

^c BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

Angiotensin II antagonist; Atenolol; Efficacy; Hydrochlorothiazide; Telmisartan; Tolerability

Indexed keywords

ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; HYDROCHLOROTHIAZIDE; TELMISARTAN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG TOLERABILITY; FATIGUE; FEMALE; HUMAN; HYPERTENSION; IMPOTENCE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SUPINE POSITION; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME;

EID: 0035153980     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(01)80034-5     Document Type: Article

References (30)

1. Angiotensin II receptors and angiotensin II receptor antagonists
2. Angiotensin-II receptors: New targets for antihypertensive therapy
3. Effects on binding characteristics and renal function of the novel, non-peptide angiotensin II antagonist BIBR277 in the rat
4. 6-Substituted benzimidazoles as new nonpeptide angiotensin II receptor antagonists: Synthesis, biological activity, and structure-activity relationships
5. Pharmacological characterization of the novel angiotensin II receptor antagonist, BIBR277
6. 1 receptor antagonist telmisartan in patients with mild to moderate hypertension
7. Acute natriuretic effect of telmisartan in hypertensive patients
8. Long-term effect of telmisartan on sodium excretion in hypertensive patients
9. Comparison of telmisartan with lisinopril in patients with mild to moderate hypertension
10. A comparison of the efficacy and duration of action of the angiotensin II receptor blocker telmisartan to amlodipine
11. ABPM comparison of the antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild-to-moderate hypertension
12. The Fifth Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC-V)
13. Rommendations for routine blood pressure measurement by indirect cuff sphygmomanometry
14. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC-VI)
15. Hypertension panel: JNC-V guidelines are too restrictive
16. Systemic hypertension: Therapy
17. Cellular localization and regional distribution of an angiotensin II-forming chymase in the heart
18. Improving outcomes in congestive heart failure: Val-HeFT
19. Candesartan in Heart Failure-Assessment of Reduction in Mortality and Morbidity (CHARM): Rationale and design
20. The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial of cardiovascular events in hypertension: Rationale and design
21. Enhancing cardiac protection after myocardial infarction: Rationale for newer clinical trials of angiotensin receptor blockers
22. Comparison of the effects of losartan and captopril on mortality in patients after myocardial infarction: The OPTIMAAL trial design
23. Blood pressure and isolated systolic hypertension and the risk of coronary heart disease and mortality in elderly men (the Zutphen Elderly Study)
24. Influence of systolic and diastolic blood pressure on stroke risk: A prospective observational study
25. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension
26. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension
27. Is diastolic hypertension an independent risk factor for stroke in the presence of normal systolic blood pressure in the middle-aged and elderly?
28. The place of combination therapy in the treatment of hypertension in 1993
29. Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension
30. A risk-benefit assessment of losartan potassium in the treatment of hypertension